Shadin Ghabra, M.D.
- Center for Cancer Research
- National Cancer Institute
- Biulding 10, Room 3B45
- Bethesda, MD 20892
- 240-858-7572
- shadin.ghabra@nih.gov
RESEARCH SUMMARY
Shadin Ghabra is a surgical oncology fellow focusing on liver immunology and immunotherapy in hepatocellular carcinoma. Shadin received her M.D degree from the University of Sharjah, United Arab Emirates (U.A.E). After graduation, she then completed an ACGME accredited 5-year general surgery training obtaining the Arab Board of Health Specializations for General Surgery (ABHS-GS). Shadin worked as a research fellow at Houston Methodist Hospital, division of Minimally Invasive Colon and Rectal Surgery in Houston, TX. She also completed the post graduate High-Impact Cancer Research program at Harvard Medical School, Boston, MA. Prior research includes metastatic colorectal cancer, cytoreduction, and HIPEC. Shadin then continued as a general surgery resident at MedStar Georgetown University Hospital in Washington, DC. Her research in Dr. Greten’s lab focuses on liver immunology and the effects of immunotherapy in hepatocellular carcinoma post resection.
Areas of Expertise
Biography
Shadin Ghabra, M.D.
Shadin Ghabra is a surgical oncology fellow focusing on liver immunology and immunotherapy in hepatocellular carcinoma. Shadin received her M.D degree from the University of Sharjah, United Arab Emirates (U.A.E). After graduation, she then completed an ACGME accredited 5-year general surgery training obtaining the Arab Board of Health Specializations for General Surgery (ABHS-GS). Shadin worked as a research fellow at Houston Methodist Hospital, division of Minimally Invasive Colon and Rectal Surgery in Houston, TX. She also completed the post graduate High-Impact Cancer Research program at Harvard Medical School, Boston, MA. Shadin then continued as a general surgery resident at MedStar Georgetown University Hospital in Washington, DC. Her research in Dr. Greten’s lab focuses on liver immunology and the effects of immunotherapy in hepatocellular carcinoma post resection.